Very Short Dual Antiplatelet Therapy after Drug-eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2 Trial

Hirotoshi Watanabe,Takenori Domei,Takeshi Morimoto,Masahiro Natsuaki,Hiroki Shiomi,Toshiaki Toyota,Masanobu Ohya,Satoru Suwa,Kensuke Takagi,Mamoru Nanasato,Yoshiki Hata,Masahiro Yagi,Nobuhiro Suematsu,Takafumi Yokomatsu,Itaru Takamisawa,Masayuki Doi,Toshiyuki Noda,Hideki Okayama,Yoshitane Seino,Tomohisa Tada,Hiroki Sakamoto,Kiyoshi Hibi,Mitsuru Abe,Kazuya Kawai,Koichi Nakao,Kenji Ando,Kengo Tanabe,Yuji Ikari,Keiichi Igarashi Hanaoka,Yoshihiro Morino,Ken Kozuma,Kazushige Kadota,Yutaka Furukawa,Yoshihisa Nakagawa,Takeshi Kimura

Very Short Dual Antiplatelet Therapy after Drug-eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2 Trial

2019

Optimal antithrombotic therapy after percutaneous coronary interventions in high bleeding risk (HBR) patients is an important issue under active discussion. However, no previous study has compared ...

Keywords:

Diabetes mellitus
Drug-eluting stent
Cardiology
Internal medicine
Medicine

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations